{"id":45642,"date":"2022-06-29T16:02:01","date_gmt":"2022-06-29T14:02:01","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/"},"modified":"2022-06-29T16:02:01","modified_gmt":"2022-06-29T14:02:01","slug":"neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/","title":{"rendered":"Neutrophil Elastase Inhibitor Therapeutics Pipeline Report 2022: Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4382719\/neutrophil-elastase-inhibitor-pipeline-insight?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=bcxljp&amp;utm_campaign=1719873+-+Neutrophil+Elastase+Inhibitor+Therapeutics+Pipeline+Report+2022%3A+Analysis+by+Developmental+Stage%2C+Associated+Indications%2C+Route+of+Administration+and+Molecule+Type&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Neutrophil Elastase Inhibitor &#8211; Pipeline Insight, 2022&#8221;<\/a> clinical trials has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220629005689\/en\/1500811\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220629005689\/en\/1500811\/21\/logo.jpg\"><\/a><\/p>\n<p>\n&#8220;Neutrophil Elastase Inhibitor &#8211; Pipeline Insight, 2022&#8221; report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Neutrophil Elastase Inhibitor development.\n<\/p>\n<p>\nThe report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.\n<\/p>\n<p>\n<strong>Descriptive coverage of pipeline development activities for Neutrophil Elastase Inhibitor<\/strong>\n<\/p>\n<p>\nPipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&amp;D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.\n<\/p>\n<p>\n<strong>Pipeline Therapeutics assessment of products for Neutrophil Elastase Inhibitor<\/strong>\n<\/p>\n<p>\nThe report assesses the active Neutrophil Elastase Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.\n<\/p>\n<p>\n<strong>Reasons to Buy<\/strong>\n<\/p>\n<ul>\n<li>\nEstablish a comprehensive understanding of the current pipeline scenario across Neutrophil Elastase Inhibitor to formulate effective R&amp;D strategies\n<\/li>\n<li>\nAssess challenges and opportunities that influence Neutrophil Elastase Inhibitor research &amp; development (R&amp;D)\n<\/li>\n<li>\nGather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage\n<\/li>\n<li>\nIdentify and understand the sought after therapy areas and indications for Neutrophil Elastase Inhibitor\n<\/li>\n<li>\nIdentify the product attributes and use it for target finding, drug repurposing, and precision medicine\n<\/li>\n<li>\nDevise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Neutrophil Elastase Inhibitor to enhance and expand business potential and scope\n<\/li>\n<li>\nPlan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress\n<\/li>\n<li>\nThe extensive domain knowledge on therapy areas supports the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>1. Report Introduction<\/strong>\n<\/p>\n<p>\n<strong>2. Neutrophil Elastase Inhibitor &#8211; Overview<\/strong>\n<\/p>\n<p>\n<strong>3. Pipeline Therapeutics<\/strong>\n<\/p>\n<ul>\n<li>\nAn Overview of Pipeline Products for Neutrophil Elastase Inhibitor\n<\/li>\n<\/ul>\n<p>\n<strong>4. Comparative Analysis<\/strong>\n<\/p>\n<p>\n<strong>5. Neutrophil Elastase Inhibitor Pipeline Products in Clinical Stages<\/strong>\n<\/p>\n<ul>\n<li>\nProduct Description\n<\/li>\n<li>\nResearch and Development\n<\/li>\n<li>\nProduct Development Activities\n<\/li>\n<\/ul>\n<p>\n<strong>6. Neutrophil Elastase Inhibitor Pipeline Products in Non-clinical Stages<\/strong>\n<\/p>\n<ul>\n<li>\nProduct Description\n<\/li>\n<li>\nResearch and Development\n<\/li>\n<li>\nProduct Development Activities\n<\/li>\n<\/ul>\n<p>\n<strong>7. Therapeutic Assessment: Active Products<\/strong>\n<\/p>\n<ul>\n<li>\nPipeline Assessment by Route of Administration\n<\/li>\n<li>\nPipeline Assessment by Stage and Route of Administration\n<\/li>\n<li>\nPipeline Assessment by Molecule Type\n<\/li>\n<li>\nPipeline Assessment by Stage and Molecule Type\n<\/li>\n<\/ul>\n<p>\n<strong>8. Inactive Pipeline Products<\/strong>\n<\/p>\n<ul>\n<li>\nProduct Description\n<\/li>\n<li>\nResearch and Development\n<\/li>\n<li>\nProduct Development Activities\n<\/li>\n<li>\nReason for dormancy\/discontinuation\n<\/li>\n<\/ul>\n<p>\n<strong>Companies Mentioned<\/strong>\n<\/p>\n<ul>\n<li>\nAstrazeneca\n<\/li>\n<li>\nOno Pharmaceuticals\n<\/li>\n<\/ul>\n<p>\nFor more information about this clinical trials report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/4382719\/neutrophil-elastase-inhibitor-pipeline-insight?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=bcxljp&amp;utm_campaign=1719873+-+Neutrophil+Elastase+Inhibitor+Therapeutics+Pipeline+Report+2022%3A+Analysis+by+Developmental+Stage%2C+Associated+Indications%2C+Route+of+Administration+and+Molecule+Type&amp;utm_exec=chdo54prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/lfuija<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#116;&#111;&#x3a;&#x70;&#114;e&#x73;&#115;&#64;&#x72;&#x65;&#115;e&#x61;&#114;c&#x68;&#x61;&#110;d&#x6d;&#97;r&#x6b;&#x65;&#116;s&#x2e;&#99;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#112;&#x72;e&#115;&#x73;&#64;&#x72;&#x65;&#115;&#x65;a&#114;&#x63;h&#97;&#x6e;&#100;&#x6d;a&#114;&#x6b;e&#116;&#x73;&#46;&#x63;&#x6f;&#109;<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Neutrophil Elastase Inhibitor &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. &#8220;Neutrophil Elastase Inhibitor &#8211; Pipeline Insight, 2022&#8221; report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Neutrophil Elastase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45642","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neutrophil Elastase Inhibitor Therapeutics Pipeline Report 2022: Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neutrophil Elastase Inhibitor Therapeutics Pipeline Report 2022: Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Neutrophil Elastase Inhibitor &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. &#8220;Neutrophil Elastase Inhibitor &#8211; Pipeline Insight, 2022&#8221; report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Neutrophil Elastase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-29T14:02:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220629005689\/en\/1500811\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Neutrophil Elastase Inhibitor Therapeutics Pipeline Report 2022: Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-06-29T14:02:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\\\/\"},\"wordCount\":502,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220629005689\\\/en\\\/1500811\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\\\/\",\"name\":\"Neutrophil Elastase Inhibitor Therapeutics Pipeline Report 2022: Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220629005689\\\/en\\\/1500811\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-06-29T14:02:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220629005689\\\/en\\\/1500811\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220629005689\\\/en\\\/1500811\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neutrophil Elastase Inhibitor Therapeutics Pipeline Report 2022: Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neutrophil Elastase Inhibitor Therapeutics Pipeline Report 2022: Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Neutrophil Elastase Inhibitor Therapeutics Pipeline Report 2022: Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Neutrophil Elastase Inhibitor &#8211; Pipeline Insight, 2022&#8221; clinical trials has been added to ResearchAndMarkets.com&#8217;s offering. &#8220;Neutrophil Elastase Inhibitor &#8211; Pipeline Insight, 2022&#8221; report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Neutrophil Elastase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-29T14:02:01+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220629005689\/en\/1500811\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Neutrophil Elastase Inhibitor Therapeutics Pipeline Report 2022: Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type &#8211; ResearchAndMarkets.com","datePublished":"2022-06-29T14:02:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/"},"wordCount":502,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220629005689\/en\/1500811\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/","name":"Neutrophil Elastase Inhibitor Therapeutics Pipeline Report 2022: Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220629005689\/en\/1500811\/21\/logo.jpg","datePublished":"2022-06-29T14:02:01+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220629005689\/en\/1500811\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220629005689\/en\/1500811\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/neutrophil-elastase-inhibitor-therapeutics-pipeline-report-2022-analysis-by-developmental-stage-associated-indications-route-of-administration-and-molecule-type-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Neutrophil Elastase Inhibitor Therapeutics Pipeline Report 2022: Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45642"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45642\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}